I totally forgot about the Myocell product line. I think I was so focused on the adipocell that I forgot that Myocell already passed phase I clinical trials, etc.In that regard the RTT laws are immensely important to USRM and getting these treatments out. In the last Q10, it stated USRM was actively seeking for a partner to expedite the process in getting these myocell products to the patients. The way it sounded, they are in active negotiations in finding this partner. In that sense news can drop at any moment about a partnership deal, which would be huge for us investors. Also Having Todd Halpren representing us in the DOJ investigation puts me at ease knowing we have an insider who knows his way around the legal system when it comes FDA regulations. In the legal defense we don't necessarily have to win outright, all we have to do is prove that the guidelines aren't clear when it comes to the cellular manipulation of adipose tissue,and that due to the unclarity the fda can't seize or stop operations. Which i think the Venable law firm is going to try to prove. With the RTT, a partnership, and a legal win against the FDA we're talking about over a 20 million dollar market cap this year and within 2-4 years we could be talking about 100 million market cap, if not more. All who are patient will be having the banks calling us asking how to invest the millions we're going to earn from this stock. Just my opinion. sell you shares, buy more shares it's a free country do whatever makes you happy!!
-RainMaker3 out
News 
Market Data 
Discover 
